Anthony Tony Pinkerton

Anthony (“Tony”) Pinkerton, Ph.D., brings nearly 20 years of drug discovery experience from a wide range of environments. Previously, Tony was the vice president of chemistry drug discovery at Sanford Burnham Prebys (SBP). At SBP, Tony led the chemistry team in the discovery and development of numerous first-in-class agents across a range of therapeutic areas. Tony maintains an adjunct faculty appointment at SBP. Prior to SBP, Tony held leadership positions at Ardea Biosciences (acquired by AstraZeneca for $1.26B) and Kalypsys Pharmaceuticals. He began his industrial career at Merck & Co., where he was a research fellow. He has co-authored more than 80 peer-reviewed publications and is an inventor on more than 40 patents and patent applications.

Tony did his undergraduate work at the University of California, San Diego, where he received a B.S. in chemistry (summa cum laude). He then was a Fulbright Fellow at the Eidgenössische Technische Hochschule (ETH)-Zürich. He subsequently earned his Ph.D. in synthetic organic chemistry from Stanford University.